Complex PCI subsets I

Dr Billal Patel is Head of Interventional Cardiology at Lancashire Cardiac Centre (Blackpool, UK). He trained as a cardiologist in Liverpool, He obtained his PhD in Coronary Microvascular Dysfunction from the University of Liverpool. United Kingdom before moving to the Lancashire Cardiac Centre. He has presented TCT, EuroPCR and ACI. His special interests include ultra low contrast PCI, intracoronary imaging, left main bifurcations, mentorship for trainees and education. Research interests include coronary physiology and microvascular dysfunction. Some of his additional interests are Brazilian Jiu-jitsu and hill walking.

Dr Breda Hennessey is an interventional cardiology fellow at Hospital Clínico San Carlos. She Graduated from the Third Faculty of Medicine in Charles University in Prague. Following this ,she returned to Ireland in 2011. She completed her Internal Medicine training in 2014 and General Cardiology training in 2019 through the Royal College of Physicians in Ireland. She was awarded the Brian McGovern Scholarship by the Irish Cardiac Society in 2019 and commenced her clinical and research fellowship at Hospital Clínico San Carlos last November. She Is currently working as an assistant PI in the ongoing DCR4 contrast study, a multicentred prospective randomised study, investigating the impact of new technologies in reducing contrast burden in complex PCI . She is also involved with the complex PCI subset, including the CTO programme at Hospital Clínico San Carlos.

Dr. Dejan Milasinovic is an interventional cardiologist at the Department of Cardiology, Clinical Center of Serbia. He is also an Assistant Professor at Faculty of Medicine, University of Belgrade. His main research interests focus in the fields of the invasive treatment of acute coronary syndromes and complex coronary interventions, with an emphasis on bifurcation PCI and intracoronary guidance. In 2016, Dr. Milasinovic received the EuroPCR 2016 Best Abstract award, for a work on the timing of invasive coronary intervention in patients with non-ST-segment elevation myocardial infarction. He is a member of European Association of Percutaneous Cardiovascular Interventions (EAPCI) and has served as program committee member of the annual EuroPCR conference. Dr. Milasinovic also serves on the editorial boards of EuroIntervention (editorial consultant) and PCRonline, and is the Cahir of the Young EAPCI/PCR Journal Club at www.pcronline.com.

Dr Justin Davies is founder and CEO of Wondr Medical, inventor of IFR, and clinical academic and consultant interventional cardiologist at the National Heart and Lung Institute, Imperial College London.